- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Interleukin 31.
Displaying page 1 of 1.
EudraCT Number: 2012-005713-39 | Sponsor Protocol Number: 42970 | Start Date*: 2014-09-02 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC) | ||
Medical condition: multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002202-37 | Sponsor Protocol Number: 2015-115 | Start Date*: 2016-01-06 |
Sponsor Name:radboudumc | ||
Full Title: Pilot study: Is concomitant administration of lidocaine during oxaliplatin infusion able to prevent pain as a result of oxaliplatin induced acute neuropathy? | ||
Medical condition: Acute oxaliplatin induced neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000649-77 | Sponsor Protocol Number: C0743T26 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Centocor BV | |||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003444-30 | Sponsor Protocol Number: C0743T12 | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000834-36 | Sponsor Protocol Number: 43806 | Start Date*: 2013-09-26 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Simvastatin addition to improve symptoms, cognition and metabolic syndrome in patients with recent-onset schizophrenia. | ||
Medical condition: Schizophrenia, schizoaffective or schizophreniform disorder (DSM-IV 295.*) or psychosis NOS (not otherwise specified) (298.9) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-001490-95 | Sponsor Protocol Number: ESPRIT 002: STALWART | Start Date*: 2006-04-21 |
Sponsor Name:National Institute of Allergy and Infectious Diseases (NIAID) | ||
Full Title: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005406-54 | Sponsor Protocol Number: M14TIL | Start Date*: 2014-05-09 | ||||||||||||||||
Sponsor Name:Antoni van Leeuwenhoek ziekenhuis | ||||||||||||||||||
Full Title: Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab... | ||||||||||||||||||
Medical condition: Patients with unresectable and metastatic (stage IIIc and stage IV) melanoma will be randomized to either treatment arm A (ipilimumab) or treatment arm B (TIL) after metastasectomy and feasibility ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001389-10 | Sponsor Protocol Number: IASO | Start Date*: 2017-09-28 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust & University of Cambridge | |||||||||||||
Full Title: A phase II randomised placebo controlled double blinded trial of Interleukin 1 blockade in Acute Severe Colitis | |||||||||||||
Medical condition: Acute Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005180-33 | Sponsor Protocol Number: CNTO328STM2001 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with So... | |||||||||||||
Medical condition: Malignant solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001897-26 | Sponsor Protocol Number: C0328T05 | Start Date*: 2006-09-07 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 2 Multicenter Study of CNTO 328 (Anti Interleukin 6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: relapsed or refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005951-19 | Sponsor Protocol Number: APL-D-003-20 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalisation for Management... | |||||||||||||
Medical condition: moderate COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BG (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001785-29 | Sponsor Protocol Number: ARIS2 | Start Date*: 2016-08-15 |
Sponsor Name:St. Vincent's University Hospital | ||
Full Title: Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment | ||
Medical condition: Cystic fibrosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000880-34 | Sponsor Protocol Number: 207489 | Start Date*: 2017-10-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002977-24 | Sponsor Protocol Number: 209538 | Start Date*: 2019-04-03 | |||||||||||
Sponsor Name:GlaxoSmithKline S.A. | |||||||||||||
Full Title: A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to... | |||||||||||||
Medical condition: Healthy volunteers (chronic obstructive pulmonary disorder [COPD])) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FI (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003632-25 | Sponsor Protocol Number: 206713 | Start Date*: 2021-06-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with sev... | |||||||||||||
Medical condition: Severe uncontrolled asthma with an eosinophilic phenotype | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) CZ (Completed) PL (Completed) IT (Completed) ES (Ongoing) IE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
